7,12-Dimethylbenzanthracene; 7,12-Dimethyltetraphene; 1,4-Dimethyl-2,3-benzophenanthrene
|Jmol 3D model||Interactive image|
|Molar mass||256.35 g·mol−1|
|Melting point||122 to 123 °C (252 to 253 °F; 395 to 396 K)|
|Main hazards||T (Toxic)|
|S-phrases||S53 S36/37 S45|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen. DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis. This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
- 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
- Miyata M; Furukawa M; Takahashi K; Gonzalez FJ; Yamazoe Y (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol. 86: 302–309. doi:10.1254/jjp.86.302.
- Sung YM; He G; Fischer, SM (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res. 65: 9304–9311. doi:10.1158/0008-5472.can-05-1015.